Company: PSTV
Filing Date: 2025-06-09
Form Type: DRS
Source: 0000950123-25-005986
Chunk: 6

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-09
Form: DRS
Chunk 6
---
 are also available, free of charge, at www.sec.gov. Information contained on, or that can be accessed
through, the websites referenced in this prospectus are not a part of, or incorporated by reference into, this prospectus.

1

Confidential Treatment Requested by Plus Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83

THE OFFERING

| Shares of our common stock outstanding prior to this offering (as of March, 2025) | [ ] shares of our common stock. |

| Shares of our common stock to be outstanding after this offering | [ ] shares of our common stock, assuming the sale of all the shares of common stock registered hereunder to Lincoln Park under the Purchase Agreement. The actual number of shares outstanding after this offering will vary depending upon the 
 actual number of shares we sell to Lincoln Park under the Purchase Agreement after the date of this prospectus.                                                                                                                                 |

| Use of proceeds | We will receive no proceeds from the sale of shares of our common stock by Lincoln Park in this offering. We may receive up to $[ ] million aggregate gross proceeds under the Purchase Agreement from any sales of shares of our common stock   
 we make to Lincoln Park pursuant to the Purchase Agreement, assuming that we sell the full amount of our common stock that we have the right, but not the obligation to sell to Lincoln Park under the Purchase Agreement. Through [ ], 2025, we 
 have received $[ ] million under the Purchase Agreement. Any proceeds that we receive from sales of shares of our common stock to Lincoln Park under the Purchase Agreement will be used for working capital and general corporate purposes. See 
 “Use of Proceeds.”                                                                                                                                                                                                                               |

| Nasdaq symbol for our common stock | “PSTV” |

| Risk factors | This investment involves a high degree of risk. See “Risk Factors” beginning on page [ ] of this prospectus for a discussion of factors you should carefully consider before deciding to invest in our securities. |

Unless otherwise noted, the number of shares of common stock to be outstanding immediately after this offering is based on [ ] shares outstanding as of [ ], 2025 and excludes, as of [ ], 2025:

| • |     | [ ] shares of common stock issuable upon exercise of stock options outstanding under our equity incentive 
 plans, with a weighted-average exercise price of $[ ] per share;                                          |

| • |